CK-19和Galectin-3在甲状腺良恶性组织中的表达

Expression of Cytokeratin-19 and Galectin-3 in Tissues from Patients with Benign and Malign Thyroid Lesions

目的探讨细胞角蛋白(CK)-19、半乳糖凝集素(Galectin)-3在甲状腺良恶性病变组织中的表达及在鉴别诊断中的意义。方法应用逆转录酶-聚合酶链反应(RT-PCR)检测甲状腺癌、良性病变及癌旁组织中CK-19、Galectin-3mRNA的表达情况,然后应用免疫组化S-P法对相同标本的石蜡包埋组织中2个指标的蛋白表达情况进行了检测。结果RT-PCR结果显示,CK-19和Galectin-3在甲状腺癌、良性病变和癌旁组织中的表达均有显著性差异(分别χ2=26.28,P<0.001;χ2=20.06,P<0.001),但是,两者的表达与临床病理参数无关。Galectin-3在不同类型的甲状腺癌中表达率有所不同,但无显著性差异,CK-19在乳头状癌中的表达要高于滤泡癌和髓样癌,有显著性差异。免疫组化的结果显示,在甲状腺癌组织中,2种标志物多数呈阳性,个别为弱阳性,而与癌组织相邻的癌旁组织多数为阴性,甲状腺良性病变组织中,除个别局灶性阳性外均为阴性。结论CK-19和Galectin-3在甲状腺癌中的表达上调,两者联合后对于甲状腺病变的诊断具有一定的临床实用价值。

Objective To study the expression of cytokeratin-19 and Galectin-3 in tissues from benign and malignant thyroid lesions and to evaluate its usefulness in the differential diagnoses. Methods The expression of CK-19 and Galectin-3 mRNA in tissues from thyroid carcinoma, adenoma and paraneoplastic tissues was detected by reverse transcfiptase-polymerase chain reaction. Immunohistochemical analysis was also performed to detect the expression of the CK-19 and Galectin-3 protein in the same samples. Results Both CK-19 and Galectin-3 mRNA were highly expressed the in tissues from the thyroid carcinoma adenoma and paraneoplastic tissue （P 〈 0. 001 ） , but there expression was not correlated with the clinicopathologic parameters. There was no significant difference between the expression of Galectin-3 mRNA and the different types of thyroid carcinoma. The expression of CK-19 was significantly higher in papillary thyroid carcinoma than that in follicular and medullary thyroid carcinoma. Immunohistochemical studies showed that both CK-19 and Galectin-3 protein were positively expressed in most of the thyroid carcinoma tissues. The expression of CK-19 and Galectin-3 protein was negative in most of the paraneoplastic tissues, and it was negative in almost all the benign lesions. Conclusion The expression of CK-19 and Galectin-3 was up-regulated in thyroid carcinoma. It might be helpful in the diagnosis of thyroid lesions by the combined analyses of the expression of the two markers.